reporting_entity_name	reporting_entity_type	last_reported_on	version	plan_name	plan_id_type	plan_id	plan_market_type	last_updated_on	out_of_network.name	out_of_network.billing_code_type	out_of_network.billing_code_type_version	out_of_network.billing_code	out_of_network.description	out_of_network.allowed_amounts.service_code	out_of_network.allowed_amounts.billing_class	out_of_network.allowed_amounts.tin.type	out_of_network.allowed_amounts.tin.value	out_of_network.allowed_amounts.payments.allowed_amount	out_of_network.allowed_amounts.payments.billing_code_modifier	out_of_network.allowed_amounts.payments.providers.billed_charge	out_of_network.allowed_amounts.payments.providers.npi
Cigna Health Life Insurance Company	Group Health Plan		1.0.0	NATIONAL OAP CIGNA Health and Life Insurance Company	ein	59-1031071	group	2022-12-01	COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	81.0	professional	ein	853312450.0	75.0	90	250.0	1033701701.0
Cigna Health Life Insurance Company	Health Insurance Issuer	2022-12-01	1.0.0						COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	11.0	professional	ein	731682257.0				
Cigna Health Life Insurance Company	Health Insurance Issuer	2022-12-01	1.0.0						COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	81.0	professional	ein	831342609.0	41.38			
Cigna Health Life Insurance Company	Health Insurance Issuer	2022-12-01	1.0.0						COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	81.0	professional	ein	873102949.0	33.75	QW		
Cigna Health Life Insurance Company	Health Insurance Issuer	2022-12-01	1.0.0						COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	81.0	professional	ein	452989041.0	33.75	QW		
Cigna Health Life Insurance Company	Health Insurance Issuer	2022-12-01	1.0.0						COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	81.0	professional	ein	845176341.0	33.75	QW		
Cigna Health Life Insurance Company	Health Insurance Issuer	2022-12-01	1.0.0						COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	81.0	professional	ein	208833340.0	33.75	QW		
Cigna Health Life Insurance Company	Health Insurance Issuer	2022-12-01	1.0.0						COV-19 AMP PRB HGH THRUPUT	HCPCS	2022.0	U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R					41.38			
